Hypothesis

Individual pain tolerance, measured by pressure pain threshold, inversely correlates with CDKN2A/B promoter acetylation and p16^INK4a expression in peripheral immune cells, such that higher pain tolerance reflects a younger epigenetic biological age.

Mechanistic Rationale

Chronic low‑grade inflammaging drives SIRT7 depletion, leading to increased acetylation of H3K9Ac and H3K18Ac at the CDKN2A/p16 promoter [2]. Elevated p16^INK4a promotes senescence of nociceptor‑associated macrophages and Schwann cells, altering cytokine release that sensitizes dorsal root ganglia neurons and lowers pain threshold. Conversely, robust vagal tone maintains NAD+ levels, sustaining SIRT7 activity and restraining p16 expression; high vagal tone also raises pain tolerance via afferent anti‑inflammatory pathways. Exercise‑induced TNF demethylation in muscle and leukocytes occurs without altering CDKN2A/B methylation [3], indicating that pain‑linked modulation of CDKN2A/B acts through histone acetylation rather than DNA methylation.

Testable Predictions

1. Individuals with high pressure pain thresholds will show significantly lower H3K9Ac/H3K18Ac enrichment at the CDKN2A/p16 promoter in circulating leukocytes compared with low‑tolerance individuals (Spearman’s r < –0.3, p < 0.01).
2. Blood p16^INK4a mRNA levels will mediate the relationship between pain tolerance and epigenetic age clocks (e.g., GrimAge), accounting for >20% of the variance.
3. Acute vagal stimulation (transcutaneous auricular VNS) will increase pain threshold and reduce CDKN2A/B promoter acetylation within 2 hours.
4. Pharmacological activation of SIRT7 (e.g., with MDL‑801) in human peripheral blood mononuclear cells ex vivo will decrease p16 expression and increase pain tolerance in a subsequent pain assay.

Potential Experiments

• Human cohort: Recruit 120 adults stratified by age (20‑70 yr). Measure pressure pain threshold with a dolorimeter, collect peripheral blood for ChIP‑qPCR of H3K9Ac/H3K18Ac at CDKN2A/p16, quantify p16 mRNA (RT‑qPCR), and compute epigenetic age using GrimAge. Perform mediation analysis.
• Intervention: Random subset receives 20 min of transcutaneous VNS vs sham; repeat pain threshold and ChIP‑qPCR pre‑ and post‑session.
• Ex‑vivo treatment: Isolate PBMCs, treat with SIRT7 activator or control, assess p16 promoter acetylation and p16 mRNA, then co‑culture with differentiated nociceptor‑like cells to evaluate neuronal sensitization via calcium imaging.

Implications

If validated, pain tolerance would serve as a low‑cost, non‑invasive proxy for the epigenetic state of the CDKN2A/B senescence locus, bridging subjective sensory experience with molecular aging biomarkers. This could accelerate aging‑intervention trials by using pain‑based phenotyping as an early readout of senolytic or SIRT‑modulating efficacy, while also highlighting the autonomic‑immune axis as a lever for modulating biological age.